Search results for "carcinogenesis"

showing 10 items of 6434 documents

Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL Sensitivity of Colon Cancer Cells

2020

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is considered to be a promising antitumor drug because of its selective proapoptotic properties on tumor cells. However, the clinical application of TRAIL is until now limited because of the resistance of several cancer cells, which can occur at various levels in the TRAIL signaling pathway. The role of decoy receptors that can side-track TRAIL, thereby preventing the formation of an activated death receptor, has been extensively studied. In this study, we have focused on extracellular vesicles (EVs) that are known to play a role in cell-to-cell communication and that can be released by donor cells into the medium transferring …

0301 basic medicineENDOCYTOSISTRAILSURFACE EXPRESSIONCell and Developmental Biology03 medical and health sciences0302 clinical medicineSecretionDR5Decoy receptorsReceptorlcsh:QH301-705.5Original Researchreceptor-ligand traffickingEXOSOMESChemistryapoptosisCell BiologyMicrovesiclesconditioned medium030104 developmental biologylcsh:Biology (General)Apoptosis030220 oncology & carcinogenesisCancer cellCancer researchTumor necrosis factor alphareceptor–ligand traffickingextracellular vesiclesDecoyDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

MODULATION OF GRO-ALPHA AND TNF-ALPHA PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS TREATED WITH KILLED HELICOBACTER PYLORI.

2007

GRO-alpha seems to play an important role in recruiting and activating neutrophils during Helicobacter pylori infection. In the present study, we examined how treatment with killed H. pylori or/and live H. pylori may differentially influence the in vitro GRO-alpha and TNF-alpha release by peripheral blood mononuclear cells (PBMC). The amounts of TNF-alpha and GRO-alpha produced by PBMC after stimulation with live H. pylori were higher than those produced after stimulation with a combination of killed and live H. pylori and the latter were higher than those produced after stimulation with killed H. pylori. In conclusion, the treatment of peripheral blood mononuclear cells with killed H. pyl…

0301 basic medicineEXPRESSIONImmunologyGASTRIC-MUCOSAlcsh:MedicineGASTRIC-MUCOSA; IN-VITRO; CHEMOKINE; GRANULOCYTES; EXPRESSION; INFECTION; SECRETIONGRANULOCYTESPeripheral blood mononuclear cell03 medical and health sciences0302 clinical medicineINFECTIONImmunology and AllergybiologyChemistrylcsh:RIN-VITROHelicobacter pyloribacterial infections and mycosesbiology.organism_classificationMolecular biologyCHEMOKINE030104 developmental biology030220 oncology & carcinogenesisImmunologySECRETIONlipids (amino acids peptides and proteins)
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition

2017

Although parenteral iron products have been established to medicinal use decades before, their structure and pharmacokinetic properties are not fully characterized yet. With its' second reflection paper on intravenous iron-based nano-colloidal products (EMA/CHMP/SWP/620008/2012) the European Medicine Agency provided an extensive catalogue of methods for quality, non-clinical and pharmacokinetic studies for the comparison of nano-sized iron products to an originator (EMA, 2015). For iron distribution studies, the reflection paper assumed the use of rodents. In our tests, we used a turkey fetus model to investigate time dependent tissue concentrations in pharmacological and toxicological rele…

0301 basic medicineEmbryo NonmammalianTissue concentrationsTurkeyAmylopectinDose dependenceBioequivalencePharmacologyKidneyToxicologyFerric CompoundsGlucaric Acid03 medical and health sciences0302 clinical medicinePharmacokineticsAnimalsDistribution (pharmacology)MedicineIron complexMaltoseFerric Oxide Saccharatedbusiness.industryMyocardiumGeneral MedicineDisposition030104 developmental biologyLiverTherapeutic Equivalency030220 oncology & carcinogenesisModels AnimalNanoparticlesIron-Dextran ComplexbusinessParenteral ironRegulatory Toxicology and Pharmacology
researchProduct

The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, …

2018

The re-emergence (i.e. ‘breakthrough’) of depressive symptoms despite maintenance treatment of depression with antidepressant drugs is a complex clinical phenomenon referred to as tolerance. Herein we critically appraise evidence from both pre-clinical and clinical studies, focusing on putative mechanisms as well as clinical correlates and implications of the emergence tolerance during antidepressant treatment for major depressive disorder (MDD). It is firstly unclear to what extent this phenotype reflects a pharmacological effect of an antidepressant, is driven by non-adherence, is a marker of latent bipolarity or another comorbidity, a marker of neuroprogression of the underlying disorder…

0301 basic medicineEmotional bluntingLoss of efficacyAntidepressantTreatment-resistanceSerotonergicloss of response03 medical and health sciences0302 clinical medicinetachyphylaxisMedicineRelapseswitch.Depression (differential diagnoses)treatment-resistancerelapsePharmacologyantidepressantwithdrawalbusiness.industryOperational definitionSwitchloss of efficacymedicine.diseaseComorbidity030104 developmental biologyWithdrawal030220 oncology & carcinogenesisMajor depressive disorderAntidepressantLoss of responsebusinessTachyphylaxiTolerancePsychosocialClinical psychologyPharmacological Research
researchProduct

First international descriptive and interventional survey for cholesterol and non-cholesterol sterol determination by gas- and liquid-chromatography–…

2019

International audience; Serum concentrations of lathosterol, the plant sterols campesterol and sitosterol and the cholesterol metabolite 5alpha-cholestanol are widely used as surrogate markers of cholesterol synthesis and absorption, respectively. Increasing numbers of laboratories utilize a broad spectrum of well-established and recently developed methods for the determination of cholesterol and non-cholesterol sterols (NCS). In order to evaluate the quality of these measurements and to identify possible sources of analytical errors our group initiated the first international survey for cholesterol and NCS. The cholesterol and NCS survey was structured as a two-part survey which took place…

0301 basic medicineEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryCholesterol balancechemistry.chemical_compound0302 clinical medicineEndocrinologySurveys and QuestionnairesPhytosterolABSORPTIONMedicineCholesterol absorptionPRECURSORSNormal laboratoryPhytosterols[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismSERUM PLANT STEROLSSitosterol3. Good healthCholestanolCholesterolAtherosclerosi030220 oncology & carcinogenesisCholesterol synthesisMolecular Medicinelipids (amino acids peptides and proteins)HumanCholesterol synthesisChromatography GasCholesterol synthesiCampesterolatherosclerosis; cholesterol absorption; cholesterol balance; cholesterol synthesis; phytosterols; surrogate markerLathosterolDeuterium labelledArticle03 medical and health sciencesHumansMolecular BiologyChromatographybusiness.industryCholesterolCell BiologyAtherosclerosisSitosterolsSterol030104 developmental biologychemistryChromatography Ga3121 General medicine internal medicine and other clinical medicine1182 Biochemistry cell and molecular biologyGas chromatographySurrogate markerbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionChromatography Liquid
researchProduct

Metabolic classification and intervention opportunities for tumor energy dysfunction

2021

A comprehensive view of cell metabolism provides a new vision of cancer, conceptualized as tissue with cellular-altered metabolism and energetic dysfunction, which can shed light on pathophysiological mechanisms. Cancer is now considered a heterogeneous ecosystem, formed by tumor cells and the microenvironment, which is molecularly, phenotypically, and metabolically reprogrammable. A wealth of evidence confirms metabolic reprogramming activity as the minimum common denominator of cancer, grouping together a wide variety of aberrations that can affect any of the different metabolic pathways involved in cell physiology. This forms the basis for a new proposed classification of cancer accordin…

0301 basic medicineEndocrinology Diabetes and MetabolismMetabolic reprogrammingReviewBiologyBioinformaticsBiochemistryMicrobiology03 medical and health sciences0302 clinical medicinetumor reprogrammingmedicinetumor microenvironmentMolecular BiologyTumor ecosystemTumor reprogrammingTumor microenvironmentCancerCommon denominatorMetabolismHypoxia (medical)medicine.diseaseQR1-502Metabolic pathway030104 developmental biologyCell metabolismTumor microenvironment030220 oncology & carcinogenesistumor ecosystemmedicine.symptom
researchProduct

Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level

2018

The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p &lt

0301 basic medicineEndometriumRANKlcsh:Chemistry0302 clinical medicineGene expressionProtein IsoformsendometriumReceptorlcsh:QH301-705.5SpectroscopyReceptor Activator of Nuclear Factor-kappa BbiologyGeneral MedicineMiddle AgedComputer Science ApplicationsGene Expression Regulation Neoplasticmedicine.anatomical_structureRANKL030220 oncology & carcinogenesisendometrial cancerimmunohistochemistryImmunohistochemistryFemaleAdultGene isoformAdenocarcinomaArticleCatalysisInorganic Chemistry03 medical and health sciencesmedicineHumansRNA MessengerPhysical and Theoretical ChemistryMolecular BiologyNeoplasm StagingActivator (genetics)Endometrial cancerOrganic Chemistrymedicine.diseaseEndometrial NeoplasmsAlternative Splicing030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Tissue Array Analysisgene expressionCancer researchbiology.proteinprognosisNeoplasm GradingInternational Journal of Molecular Sciences
researchProduct

The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

2020

ABSTRACT The utilization of extracellular vesicles (EVs) in clinical theranostics has rapidly advanced in the past decade. In November 2018, the International Society for Extracellular Vesicles (ISEV) held a workshop on “EVs in Clinical Theranostic”. Here, we report the conclusions of roundtable discussions on the current advancement in the analysis technologies and we provide some guidelines to researchers in the field to consider the use of EVs in clinical application. The main challenges and the requirements for EV separation and characterization strategies, quality control and clinical investigation were discussed to promote the application of EVs in future clinical studies.

0301 basic medicineEngineeringHistologytheranosticMeeting ReportFreeze thawingExtracellular vesiclesCa 19 9 antigen03 medical and health sciences0302 clinical medicineClinical investigationIn vitro studylcsh:QH573-671therapylcsh:Cytologybusiness.industryDietary intakeAntibody affinityCell BiologyExtracellular vesicles030104 developmental biology030220 oncology & carcinogenesisAntisense oligonucleotidesbiomarkerEngineering ethicsbusinessJournal of Extracellular Vesicles
researchProduct

Chip Formation and Control

2008

This chapter provides comprehensive engineering knowledge and modelling techniques applied in description of chip formation in the cutting zone and its separation from the bulk material, flow, and final breaking. Possible classification systems, including different chip shapes and physical mechanisms of their formation, are specified. The mechanisms of brittle fracture-based and shear-type chips are characterized in terms of plastic deformation and fracture mechanics. The models of the shear angle using different mechanical approaches are discussed. In addition, representative examples of FEM simulations of different types of chips for turning and milling operations are presented. Formulas …

0301 basic medicineEngineeringMaterials sciencebusiness.industryChip formationFlow (psychology)Mechanical engineeringFracture mechanicsStructural engineeringManufacturing systemsChip03 medical and health sciences030104 developmental biology0302 clinical medicineMachiningEmbedded system030220 oncology & carcinogenesisShear anglebusinessBrittle fractureComputingMethodologies_COMPUTERGRAPHICS
researchProduct